Answers are grounded in this paper and cite their sources.
Implant integration improves through glucose-responsive drug delivery in diabetes, suggesting enhanced biomaterial designs.
Implant integration is severely impacted by diabetes mellitus impaired bone formation and chronic inflammation. Pronounced fluctuations in blood glucose levels further hinder therapeutic regulation, rendering static drug-release strategies inadequate. To address this issue, we developed a trabecular tantalum implant with a porous structure mimicking cancellous bone mechanics, coated with phenylboronic acid–modified mesoporous silica nanoparticles loaded with aspirin. This design enables dynamic, glucose-responsive, dual-mode drug delivery; under normoglycemia, aspirin is released slowly to promote osteogenesis, whereas under hyperglycemia, its release is accelerated to suppress inflammation. In vitro, the coating enhanced the osteogenic differentiation of stem cells and promoted M2 macrophage polarization. In a diabetic rat defect model, this system improved osseointegration and reduced inflammatory responses. These findings indicate that we developed a metabolically adaptive implant surface that integrates trabecular tantalum with glucose-responsive nanocarriers. By coupling drug release kinetics with the metabolic status, this strategy addresses the dual obstacles of impaired osteogenesis and inflammation in diabetes and advances the development of smart biomaterials for clinical translation. • 3D-printed Ta scaffold + Glucose-triggered aspirin nanocarriers = smart diabetic implant • Dual-release kinetics: It achieves slow/sustained release of aspirin under normoglycemic conditions (5.5 mM) to exert osteogenic effects, and accelerated release under hyperglycemic conditions (>11.1 mM) to exert anti-inflammatory effects. • The porous tantalum scaffold (∼0.9 GPa modulus, matching cancellous bone) reduces stress shielding, enables bone ingrowth, and achieves high mechanical biocompatibility. • Enhanced osseointegration validated in preclinical diabetic models
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: